PLoS ONE · 2017 · 76 citations · 40 references
Life SciencesBiochemistryMolecular MedicineClinical BiochemistryLipid BiochemistryMolecular DiagnosticsBiomarkers In PathologyLipidomicsLysosomal Storage DisordersMolecular ScreeningSphingolipid MetabolismBiomarkersFabry DiseaseGaucher DiseaseKrabbe DiseaseNiemann-pick C1-like 1Niemann-pick Disease Type CSphingolipid Metabolic DisordersSphingolipidomics
BACKGROUND: The biological diagnosis of sphingolipidoses currently relies on the measurement of specific enzymatic activities and/or genetic studies. Lysosphingolipids have recently emerged as potential biomarkers of sphingolipidoses and Niemann-Pick type C in plasma. METHODOLOGY: We developed a sensitive and specific method enabling the simultaneous quantification of lysosphingolipids by LC-MS/MS: lysoglobotriaosylceramide for Fabry disease, lysohexosylceramide (i.e. lysoglucosylceramide and/or lysogalactosylceramide) for Gaucher and Krabbe diseases, lysosphingomyelin and its carboxylated analogue lysosphingomyelin-509 for Niemann-Pick type A or B, and C diseases, lysoGM1 ganglioside for GM1gangliosidosis and lysoGM2 ganglioside for GM2 gangliosidosis. FINDINGS: The diagnostic performances were validated in plasma samples analysing a large series of patients affected with sphingolipidoses and Niemann-Pick type C disease (n = 98), other inborn errors of metabolism (n = 23), and controls (n = 228). The multiplex measurement of lysosphingolipids allowed the screening of Fabry (including female patients and late-onset variants), Gaucher and infantile Krabbe, Niemann-Pick type A/B and C diseases with high sensitivity and specificity. LysoGM1 and LysoGM2 were elevated in most of the patients affected with GM1 and GM2 gangliosidosis respectively. In amniotic fluid supernatant from pregnancies presenting non-immune hydrops fetalis (n = 77, including previously diagnosed Gaucher (n = 5), GM1 gangliosidosis (n = 4) and galactosialidosis (n = 4) fetuses) and from normal pregnancies (n = 15), a specific and dramatic increase of lysohexosylceramide was observed only in the Gaucher amniotic fluid samples. INTERPRETATION: This multiplex assay which allows the simultaneous measurement of lysosphingolipids in plasma modifies the diagnostic strategy of sphingolipidoses and Niemann-Pick type C. Furthermore, in pregnancies presenting non-immune hydrops fetalis, lysohexosylceramide measurement in amniotic fluid offers a rapid screening of fetal Gaucher disease without waiting for glucocerebrosidase activity measurement in cultured amniocytes.
40
X‐chromosome inactivation in female patients with Fabry disease
Lucía Echevarría, Karelle Bénistan, Anne Toussaint et al. · Clinical Genetics · 2015 · 417 citations
The Human Chitotriosidase Gene
Rolf G. Boot, G. Herma Renkema, Marri Verhoek et al. · Journal of Biological Chemistry · 1998 · 408 citations · Full text
A comprehensive classification system for lipids
Eoin Fahy, Shankar Subramaniam, H. Alex Brown et al. · European Journal of Lipid Science and Technology · 2005 · 365 citations · Full text